Assam Enforces Lower Ceiling Rates on 137 Anti-Cancer Drugs Starting November 9 Pharmacies and hospitals across Assam must sell 137 non-scheduled cancer medicines at reduced retail prices starting November 9. The directive enforces a 30 percent trade margin cap, backed by a 90-day statewide monitoring drive. Cancer therapy in Assam is set to turn considerably more economical as the Assam Drugs Control Administration instructs all retail pharmacies, hospital dispensaries, distributors, and stockists throughout the state to dispense 137 non-scheduled anti-cancer medications at reduced maximum retail prices starting November 9. The mandatory adjustment stems from a broader nationwide pricing framework designed to curb runaway therapy expenses for patients coping with life-threatening diagnoses. The 30 Percent Trade Margin Cap and Federal Gazette Mandate The state-level enforcement executes a formal Gazette notification released on October 17 by the National Pharmaceutical Pricing Authority. Acting under Paragraph 19 of the Drugs (Prices Control) Order, 2013, which authorizes emergency market interventions in the public interest, the central authority instituted a 30 percent cap on trade margins relative to maximum retail prices for the 137 specified medicines. The regulatory ceiling extends across every non-scheduled formulation featuring these active therapeutic substances, whether distributed as stand-alone single-drug products or as mixed combinations. Patented pharmaceutical products have also been brought within the purview of the regulation, preventing manufacturers from bypassing price relief measures on proprietary molecules. Mandatory Compliance and the 90-Day Inspection Drive Under the directive issued by the Assam Drugs Control Administration, healthcare providers, retail counters, and wholesale suppliers must adopt the revised price points starting November 9 without exception. Facilities are also obligated to prominently display updated retail price lists at their service points, adhering strictly to the transparency requirements stipulated in Paragraph 25(3) of the Drugs (Prices Control) Order, 2013. To guarantee that these savings actually reach cancer patients across urban and rural zones, administrative teams will conduct a 90-day verification drive across the state. Surveillance units will scrutinize billing systems, examine dispensing records, and monitor retail counters to avert overcharging. Establishments discovered violating the prescribed ceilings will face direct legal prosecution under both the Drugs (Prices Control) Order and the Essential Commodities Act, 1955. Authorities underscored that strict adherence to the new price thresholds is legally mandatory and takes effect immediately. Curtailing Mark-ups to Slash Retail Prices by Up to 70 Percent This statutory market intervention was prompted by pricing evaluations revealing exorbitant mark-ups within the cancer care distribution pipeline. Trade mark-ups on several non-scheduled oncology drugs averaged around 170 percent, with extreme instances exceeding 700 percent between manufacturer invoice and final patient billing. Restricting intermediary distribution margins to a maximum ceiling of 30 percent is projected to drive retail shelf costs down by up to 70 percent, depending on an individual product's prior pricing structure. The 137 formulations covered by the directive encompass widely prescribed oncology treatments, including crucial immunotherapy regimens. Among the key medications governed by the revised price matrix are Nivolumab, Olaparib, Denosumab, and Topotecan. Precedent from the 2019 Regulatory Price Reform This operational move builds on an established regulatory playbook first deployed in 2019, when the National Pharmaceutical Pricing Authority implemented an identical 30 percent trade margin ceiling on 42 anti-cancer medicines. That previous policy initiative triggered sharp price reductions of up to 90 percent across 526 individual commercial brands. The complete text of the official Gazette notice, executive orders, and full itemized drug pricing schedules are hosted on the regulatory body's official website. What this means for you Capping trade margins on critical oncology treatments delivers immediate financial relief to households managing steep long-term medical bills. • Across India: The central pricing authority's order limits intermediary mark-ups to 30 percent across 137 cancer formulations nationwide. This policy intervention ensures that patients undergoing intensive therapies, including advanced immunotherapy, see shelf prices drop by up to 70 percent. • In Assam: Retail stores, hospital pharmacies, and stockists statewide must implement the revised pricing starting November 9. Patients and families can verify bills against prominently displayed updated price sheets to confirm they are not overpaying. • Retailers and Hospitals: Medical distribution networks and dispensaries must align their billing records with the revised maximum retail prices before the deadline. Non-compliant facilities face stern penalties under the Essential Commodities Act during state inspections. • Action for Caregivers: Caregivers purchasing prescribed oncology drugs should ask for receipts reflecting the updated price schedules. Any instance of overcharging can be reported directly to drug inspectors during the ongoing 90-day statewide monitoring drive. Why this happened Unregulated trade margins in the private distribution chain prompted government intervention to make life-saving oncology care affordable. • Excessive Commercial Mark-ups: Official scrutiny exposed average trade mark-ups of around 170 percent on non-scheduled oncology products, with select products priced up to 700 percent over invoice. These unchecked distribution mark-ups imposed unbearable financial burdens on patients undergoing continuous treatment. • Statutory Intervention for Public Welfare: Regulators invoked Paragraph 19 of the Drugs (Prices Control) Order, 2013, to place an emergency ceiling on intermediary profits. This specific provision grants legal authority to fix price limits when market failures threaten public health access. • Precedent of the 2019 Intervention: A comparable regulatory intervention in 2019 capped margins at 30 percent on 42 cancer medicines. That initial initiative successfully slashed retail prices by up to 90 percent across 526 brands, providing an established operational model for this expanded 137-drug measure. Questions & Answers 1. When do the reduced cancer medicine prices take effect in Assam? The Assam Drugs Control Administration has directed that the revised lower prices take effect across the state on November 9. 2. How many anti-cancer drugs are covered under this new directive? A total of 137 non-scheduled anti-cancer medications are covered under this pricing order. 3. What ceiling has been placed on the trade margin for these medicines? The National Pharmaceutical Pricing Authority capped the trade margin at 30 percent of the maximum retail price. 4. By how much are the prices of these medications expected to drop? Retail prices are anticipated to decline by up to 70 percent, depending on the previous commercial pricing structure. 5. How will the government monitor compliance across medical facilities in Assam? The state administration has launched a 90-day inspection drive to inspect dispensaries and prevent overcharging. 6. What legal repercussions do retailers face if they violate the price caps? Violators will face prosecution under the Drugs (Prices Control) Order and the Essential Commodities Act, 1955. 7. Which prominent anti-cancer therapies are listed in the regulation? The list features widely prescribed oncology drugs including Nivolumab, Olaparib, Denosumab, and Topotecan. https://trendkia.com/en/assam/assam-men-kainsara-ki-137-davaen-9-navnbara-se-hongi-sasti-sarakara-ne-taya-ki-kimaton-ki-nai-sima-55719 TrendKia — Har trend, sabse pehle.